Human immunodeficiency virus type 1 Tat protein up-regulates interleukin-13 receptor expression on renal cell carcinoma (RCC) cells (Meeting abstract).

Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.

Human immunodeficiency virus type 1 Tat protein up-regulates interleukin-13 receptor expression on renal cell carcinoma (RCC) cells (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 38:A2038 1997. Unique Identifier : AIDSLINE ICDB/98639038
Husain S; Puri R; Laboratory of Molecular Tumor Biology, Division of Cellular and; Gene Therapies, CBER, FDA, Bethesda, MD 20892

Abstract: The HIV-1 regulatory gene, tat, encodes an early transactivator protein (Tat) necessary for virus replication. This Tat protein is actively secreted by infected cells. We have recently demonstrated that constitutive expression of the tat gene in a Burkitt lymphoma cell line up-regulates interleukin-4 receptors (IL-4R). The exogenous recombinant Tat protein or supernatant of Raji-tat cells also enhanced the expression of IL-4R in RCC cell lines. Because IL-13R may share component(s) with IL-4R, we investigated whether Tat protein also regulated IL-13R on RCC cell lines. We observed that Tat protein (up to 200 ng/mL) increased IL-13R expression three-fold in WS-RCC and approx 60% in PM-RCC cell line. Cycloheximide inhibited IL-13R protein synthesis in both control (t1/2 6.2 hr) and Raji-tat supernatant treated (t1/2 5.2 hr) PM-RCC cells. This Tat-mediated up-regulation of IL-13R was abrogated by either Tat-antiserum or deactivated Raji-tat supernatant indicating Tat specificity. The ability of Tat protein to modulate expression of certain cytokine receptors on cancer cells might have important implications in understanding the pathogenesis of frequent neoplastic disorders in HIV-1 infected individuals.

Keywords: Carcinoma, Renal Cell/*METABOLISM/PATHOLOGY Gene Expression Regulation, Neoplastic/*PHYSIOLOGY Gene Products, tat/IMMUNOLOGY/*PHYSIOLOGY Human Immune Sera Interleukin-13/*GENETICS Kidney Neoplasms/*METABOLISM/PATHOLOGY Tumor Cells, Cultured *Up-Regulation (Physiology) ABSTRACT
980228
M9820757

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .